Objectives: Quality of life (QOL) data were used to evaluate the effects of self-administered intracavernosal injection of alprostadil for erectile dysfunction, when used for up to 18 months during a 13 country Phase III clinical trial. Methods: The Duke Health Pro®le was used to measure patients' physical and psychosocial QOL at baseline, 3, 6, 12 and 18 months. Changes from baseline were measured using paired t-tests, with additional analyses by cause of dysfunction, starting dosage, and prior treatment. Results: Patients displayed signi®cant improvements in mental and social health and self-esteem at six months (P`0.01, n 570), with greater improvements at 12 and 18 months. Anxiety and depression measures also improved signi®cantly at 12 and 18 months, as did the summary general health score. Worse pain scores were observed in the ®rst year but not at 18 months. Those with a starting dosage of 10±20 mg, those with psychogenic causes of dysfunction, and those with no prior treatment for erectile dysfunction generally showed the greatest improvements. Conclusion: In this study, the clinical improvements in erectile function due to intracavernosal alprostadil therapy were complemented by QOL improvements, particularly in the mental health, of many patients.
Introduction
Patients experiencing problems with sexual functioning, and men with erectile dysfunction (ED) in particular, have been shown to suffer from depressive symptoms, low self-esteem, and other signs of psychological distress, and perhaps decreased overall quality of life. 1, 2 For many individuals, sexual functioning may be an important factor determining psychosocial health. 3, 4 Erectile dysfunction results from a variety of causes and may be treated with a growing number of therapies. 5 An indicative test of a therapy for ED is its success in improving overall sexual functioning and the quality of life. Therefore, it is important to evaluate how much such a therapy alleviates broader problems in quality of life arising from this dysfunction.
This paper presents the results of quality of life evaluation done as part of an international clinical trial studying the use of intracavernosal injections of alprostadil sterile powder (prostaglandin E 1 , Caverject 1 ) for ED. 6±8 It focuses on the effects of this therapy related to mental, social, and physical functioning of patients during up to 18 months of treatment.
Methods

The clinical trial
In total, 848 male patients with ED were enrolled in 12 European countries and in South Africa during 1992±1995. Enrollees visited their physicians' of®ces until an optimum home-use dose of alprostadil was established by titration; 732 men entered the subsequent self-injection phase of the trial with the recommendation to use alprostadil 1±3 times per week. The initial trial period was six months, followed by an optional 12-month extension phase.
No placebo-control group was used because earlier studies had shown no clinical response to placebo. 9 During the initial six months of the self-injection phase of the study, 88% of injections assessed by the patients resulted in satisfactory sexual activity. Penile pain occurred at some time for 44% of patients but led to discontinuation of study medication in only 3% of the patients. Complete results are reported elsewhere. 6 
Quality of life instrument
The 17-item Duke Health Pro®le questionnaire 10 (the Duke questionnaire) was used to evaluate whether alprostadil therapy had an effect on patients' quality of life. The Duke questionnaire has a general health score based on 15 questions, as well as three primary domains (physical, mental, and social health) and seven subscale scores (the 11 scores, domains, and subscales hereafter are referred to as attributes). For general health, the three primary domains, and the subscales for perceived health and self-esteem (all referred to as measures of function), higher scores represent better quality of life. For the other ®ve attributes: anxiety, depression, anxiety/depression, disability and pain (referred to as measures of dysfunction)Ðthe reverse is true. In all cases, scores for the attributes are scaled from 0±100. The Duke was well-validated for use in a general population in the United States. 10 The Duke was translated for use among nonEnglish speaking participants in the trial. A single forward translation was made from English to each of the other languages, followed by a minimum of two blinded translations from the other languages back to English. All necessary revisions were negotiated between the translators and the original developers of the Duke. Results of efforts to validate these translations indicate that overall reliability of the translations is similar to that in a US population.
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Outcomes
The Duke questionnaire was self-administered when patients enrolled in the trial (referred to as baseline), during the trial at approximately 3, 6, 12, and 18 months after beginning self-injection, and at treatment discontinuation (if it occurred other than at one of these intervals). The primary outcome was change in the attribute scores from baseline until six months after beginning self-injection. In cases where there was no patient response at six months, the response from the most recent visit after enrollment, but prior to six months, was used. This method is equivalent to using the last observation carried forward.
The secondary outcome was change in the scores for the attributes from baseline until 3, 6, 12, and 18 months after initiation of self-injection, to determine how quickly the changes occurred and whether the effects observed at six months were maintained for a longer period. This analysis of change over time potentially confounded the effects of a changing patient population (the respondent sample was smaller at each subsequent time point) and the effects of changes in individual men's perceptions of their quality of life. To distinguish these two effects, we evaluated changes from enrollment to the latter time points for the sample of men who completed the 18 months of follow-up.
Analysis
Patient characteristics Means and ranges (for continuous variables) and percentages (for categorical variables) for relevant patient characteristics are reported. Questionnaire response rates are also described.
Changes in quality of life between baseline and six months Mean scores and their standard deviations at baseline are shown. Changes in quality of life between baseline and six months were estimated for each attribute. Paired t-tests were used to determine whether the changes were signi®cantly different from zero. Because there was a smaller questionnaire response rate among men who dropped out prior to six months than among men who completed the six months period, two estimates of these changes were made. The ®rst was an unweighted estimate among men who had responses for the primary outcome measure. However, the unweighted estimates underrepresent the effects on dropouts (who tended to have smaller improvements in quality of life) relative to completers (who tended to have larger improvements in quality of life). To adjust for this potential bias, we calculated weighted average changes, using weights which were bigger for the responses of those who dropped out prior to six months than for those who completed six months. These weights adjust the average change as if completers and dropouts had equal response rates to the questionnaires, that is, the weights are proportional to the inverse of the response rates for completers and dropouts, respectively). 12 A multivariate analysis of variance (MANOVA) was performed to determine if the combined changes in the 11 attribute scores were statistically different from zero.
Differences among patient subgroups We used a two-stage procedure to identify whether changes in the Duke scores differed for subgroups de®ned by Quality of life effects of alprostadil therapy RJ Willke et al the causes of dysfunction and the starting dosage of alprostadil. Firstly, we tested for differences among the subgroup scores at enrollment using an analysis of variance (ANOVA), for example, at enrollment, was the quality of life among patients with psychogenic causes of dysfunction similar to the quality of life of patients with neurogenic causes of dysfunction? If this test indicated that differences existed among the strata, the least signi®cant difference method was used to identify those strata that differed pairwise from one another. 13 Differences in changes in scores between baseline and six months among these subgroups were then identi®ed using the same procedure.
Changes in quality of life between baseline and 3, 6, 12, 18 months Changes in scores between baseline and 3, 6, 12, 18 months were estimated for two sets of patients. One set comprised all respondents to the Duke questionnaire at each of the time points. The second set included only men who completed 18 months of self injection. MANOVA was used to evaluate whether the changes in the responses for all of the attributes at each of the four points in time differed from 0, for example, did the changes in the scores for the 11 attributes measured at 3 months differ from 0? Only unweighted results are used here because small cell sizes among dropouts in some periods result in unreliable weights.
Statistical considerations P-values less than or equal to 0.05 were considered to represent differences that were statistically signi®cant. No adjustment was made to the critical values for the statistic tests for determining P-values. Table 1 shows demographic data and history of ED for men who entered the self-injection phase of the trial. The average age at enrollment was 52.4 y, and 93% of men were white. Psychogenic and vasculogenic causes of ED affected over 58% of the sample. Average duration of ED at baseline was 4.6 y, and 41% of men did not not receive prior treatment for their dysfunction.
Results
Patient characteristics
Among the 732 men beginning self-injection, 559 completed six months of therapy, and 570 (78%) had QOL responses usable for the primary outcome analysis. The Duke questionnaire response rate among those who completed six months was 92% (513 out of 559), while among patients who dropped out prior to six months it was 33% (57 out of 173). The weighted primary analysis adjusts for this difference in response rates, assuming that nonrespondents who dropped out of the study had responses that were similar to those of respondents who dropped out of the study, and that nonrespondents who remained in the study had responses that were similar to those of respondents who remained in the study.
Changes in quality of life between baseline and six months Table 2 shows the mean values and standard deviations for the 11 attributes of the Duke questionnaire measured at baseline. Scores were comparable across measures of function, although social health was generally lower than the others. Among measures of dysfunction, anxiety, depression, and pain all had similar levels, while there was a low level of disability. Table 2 also shows changes from baseline until six months using the last observation carried All 732 men entering self-injection study, unweighted.
Quality of life effects of alprostadil therapy RJ Willke et al Signi®cant differences (P 0.05) at study entry denoted by a a . Changes represent differences in scores between study entry and six months when available, or else closest time point to six months (see text). For general, physical, mental, social, and perceived health, and self-esteem, high scores represent good quality of life and positive changes denote improvement. For the measures of dysfunction (anxiety, depression, disability, and pain), high scores represent poor quality of life and negative changes denote improvement. All changes reported are statistically signi®cant (P 0.05).
Quality of life effects of alprostadil therapy RJ Willke et al forward analysis. Assessments of change based on both unweighted and weighted t-tests indicated that men experienced statistically signi®cant improvements in mental health, social health and self-esteem. The weighted but not the unweighted t-tests indicated a signi®cant decrement in physical health and a signi®cant increase in pain. The differences between these weighted and unweighted results indicate that responses about physical health and pain were relatively worse among patients who did not complete six months of therapy than they were among those who did. The MANOVA test of all 11 changes in scores indicated that the changes were jointly statistically signi®cant vs 0 (P 0.001).
Differences across patient subgroups Table 3 indicates that men with psychogenic causes of dysfunction had greater improvements in several areas than those with other causes of dysfunction. In addition, men whose starting dose of alprostadil was between 10±20 mg had greater improvements than men with other starting dosages, particularly those with higher initial dosages. Finally, men who had no prior treatment for erectile dysfunction had greater improvements in general health and depression than men who had had some type of previous treatment. The far right column of Table 3 indicates cases in which the means of the two subgroups also differed signi®cantly at baseline. Differences at entry were common across the causes of dysfunction, but not by starting dosage or presence of prior treatment. In all cases where baseline differences existed, the subgroup showing greater improvement at 6 months also had a worse score at baseline.
Changes in quality of life between baseline and 3, 6, 12, and 18 months Figures 1 and 2 show the changes in scores between baseline and later periods for the six measures of functioning ( Figure 1 ) and for the ®ve measures of dysfunction ( Figure 2 ) for all respondents to the Duke questionnaire. Sample sizes at speci®c time points are shown in the ®gures and include dropout scores for the period preceding the scheduled visit.
The general health, mental health, and selfesteem attributes ( Figure 1) were signi®cantly improved at all four time points; the depression and anxiety (Figure 2 ) attributes were improved from 12 months onward. No attributes showed Quality of life effects of alprostadil therapy RJ Willke et al consistent worsening over the period. While the physical health ( Figure 1 ) and pain ( Figure 2 ) scores in the primary analysis at six months were worse than at enrollment, these de®cits were not maintained throughout the trial.
While these QOL scores as a group appeared to improve quickly after initiation of therapy, the MANOVA tests indicated that statistically they ®rst became different from baseline at six months, remaining so at 12 and 18 months (P-values of 0.12, 0.02, 0.0001, and 0.0001 for 3, 6, 12, and 18 months, respectively).
The relationships observed in the overall sample were repeated in the subset of men who completed the 18 months of follow-up. The magnitude of improvement for these men was greater than that for the overall sample.
Discussion
The results of this study indicate that over an 18 month period patients receiving intracavernosal alprostadil experienced substantial improvements in several attributes of quality of life. The largest improvements occurred in mental and social health, including anxiety, depression, and self-esteem. They were present at six months after initiation of selfinjection, and tended to be larger for patients who continued in the study past six months.
There also appeared to be a worsening in the physical health and pain attributes in the ®rst six months, principally among patients who dropped out of the trial during this time. Localized pain associated with therapy or exogenous changes in physical health in this older population were probably related to patients' reasons for discontinuation. However, there was no long-term problem in these areas for patients who continued in the trial. There is no evidence of any other association between treatment and physical health. 6, 9, 14 Better improvements in mental-health related Duke scores were seen for patients with psychogenic causes of dysfunction. In general, these improvements were associated with relatively low baseline scores for psychogenic patients compared to other groups and not with relatively high treatment period scores. The greater improvements for these patients' results suggest that the mental health de®cits for this subgroup were at least partly caused by their erectile dysfunction and thus were reduced with effective treatment for the condition. 15 However, one study which included the Duke evaluation showed that among recently injured workers receiving compensation for musculoskeletal disorders, for example, acute low back pain, who reported feeling`somewhat better' or much better' three weeks after baseline, the improvement in the Duke general score was 5.58, and in the physical score was 12.68. 15 Among all the patients who completed 18 months of therapy in this trial, the general health score improvement was 2.85 and the mental health score improvement was 5.03. Given differences in the acuteness and disabling nature of musculoskeletal problems compared to erectile dysfunction, improvements of roughly 40±50% the magnitude in this study are not surprising and probably still represent meaning-ful improvements in health for many patients.
No control group was present in this clinical trial because prior studies had indicated that there was no clinical response associated with the use of placebo, thus placing ethical constraints on our ability to include a placebo group in a long-term trial. Lack of a clinical response to placebo, however, does not necessarily imply that patient quality of life would not change over time despite a lack of effective treatment; one could advance reasons why quality of life would either improve or worsen with time. To the best of our knowledge, no longitudinal study of the quality of life of untreated ED patients exists. Therefore, we cannot ®rmly conclude that the observed positive and negative changes in quality of life were attributable to the use of alprostadil. However, the fact that the improvements occurred for attributes that are known to be affected by ED, such as mental health and self-esteem, provides evidence that the changes were due to the action of the drug and to resulting improvements in sexual functioning, and not to mechanisms such as regression to the mean. This inference is also supported by the observation that improvements in quality of life were greater for men using the average 10±20 mg dosage of alprostadil compared with men using higher dosages. The need for higher doses of alprostadil generally is an indication of dif®culty achieving consistent ef®cacy and may signal a worse response to therapy, based most probably on more severe underlying patho-logical mechanisms causing ED. Similarly, the ®nding that men who had no previous treatment for ED had greater quality of life improvements than those having had prior treatment is the expected result if it is the treatment for ED which is causing the quality of life improvement.
Besides the lack of a control group, a limitation of the study is substantial non-response among those who did not complete six months of therapy. The weighting approach that we adopted to address this issue is among the family of procedures recommended for imputing missing survey data. Nevertheless, we cannot quantitatively address issues of how non-respondents might differ from respondents.
Conclusions
This study replicates and con®rms, in a multinational, multicultural setting, the quality of life improvements associated with intracavernosal alprostadil therapy seen in a separate trial conducted in the United States. 2 It indicates that alprostadil therapy not only is effective in improving erectile function but also helps improve overall sexual functioning to a degree that alleviates the broader mental and social health problems that can be associated with sexual dysfunction.
